The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy
- PMID: 19665223
- DOI: 10.1016/j.biomaterials.2009.07.038
The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy
Abstract
During endocytosis, pH-triggered release of encapsulated therapeutics from delivery carriers may accelerate their intracellular trafficking increasing therapeutic efficacy. To improve the therapeutic potential of targeted immunochemotherapy using anti-HER2/neu liposomal doxorubicin, we exploit the formation of leaky heterogeneities on rigid lipid bilayers to extensively release doxorubicin during endocytosis. We have previously demonstrated that pH-dependent formation of phase-separated lipid heterogeneities on the plane of a bilayer membrane increases the permeability of bilayers when they are composed of lipid pairs with rigid non-matching acyl chain lengths. This was suggested to be due to defective packing among lipids residing at the interfaces of lipid domains. Here we design nanometer-size antiHER2/neu-labeled PEGylated vesicles composed of lipid pairs with longer non-matching acyl chain lengths (n=18 and 21). These vesicles exhibit superior killing efficacy of cancer cells compared to established liposome formulations, and their killing efficacy is similar to the effect of combined free doxorubicin and free antiHER2/neu antibody. Other transport-related properties such as liposome blood circulation times, and specific binding and internalization by cancer cells are unaffected. These results demonstrate the potential of vesicles with pH-triggered leaky heterogeneities to increase the therapeutic potential of targeted immunochemotherapy.
Similar articles
-
Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch.Langmuir. 2008 Jun 3;24(11):5679-88. doi: 10.1021/la800331a. Epub 2008 May 10. Langmuir. 2008. PMID: 18471003
-
Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.Mol Pharm. 2011 Dec 5;8(6):2224-32. doi: 10.1021/mp200079y. Epub 2011 Sep 21. Mol Pharm. 2011. PMID: 21899300
-
Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.Biomaterials. 2012 Jun;33(17):4345-52. doi: 10.1016/j.biomaterials.2012.02.039. Epub 2012 Mar 17. Biomaterials. 2012. PMID: 22429980
-
Liposomal doxorubicin.J Drug Target. 1996;4(3):129-40. doi: 10.3109/10611869609015970. J Drug Target. 1996. PMID: 8959485 Review.
-
Use of liposomes as injectable-drug delivery systems.Am J Hosp Pharm. 1989 Aug;46(8):1576-87. Am J Hosp Pharm. 1989. PMID: 2672806 Review.
Cited by
-
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80. doi: 10.1615/critrevtherdrugcarriersyst.v26.i6.10. Crit Rev Ther Drug Carrier Syst. 2009. PMID: 20402623 Free PMC article. Review.
-
Physicochemical Stimulus-Responsive Systems Targeted with Antibody Derivatives.Curr Mol Med. 2024;24(10):1250-1268. doi: 10.2174/1566524023666230818093016. Curr Mol Med. 2024. PMID: 37594115 Review.
-
Transcriptome-wide elucidation of liposomal formulations for anticancer drug delivery.Int J Nanomedicine. 2017 Nov 29;12:8557-8572. doi: 10.2147/IJN.S148975. eCollection 2017. Int J Nanomedicine. 2017. PMID: 29238192 Free PMC article.
-
Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform.J Biomed Opt. 2015 Aug;20(8):88003. doi: 10.1117/1.JBO.20.8.088003. J Biomed Opt. 2015. PMID: 26315280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous